Published in Clin Pharmacol Ther on December 01, 1979
Oxprenolol absorption in man after single bolus dosing into two segments of the colon compared with that after oral dosing. Br J Clin Pharmacol (1985) 0.96
The effect of topical local anesthetics on thermal pain sensitivity in patients with irritable bowel syndrome. Pain Res Treat (2012) 0.81
Bupivacaine administered intrathecally versus rectally in the management of intractable rectal cancer pain in palliative care. Onco Targets Ther (2014) 0.75
Comparison of physicochemical properties of suppositories containing starch hydrolysates. Saudi Pharm J (2016) 0.75
Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis (1989) 4.79
Quantitative study on the production and kinetics of mononuclear phagocytes during an acute inflammatory reaction. J Exp Med (1973) 2.94
Therapeutic drug monitoring in saliva. Clin Pharmacokinet (1978) 2.66
The influence of cytokines on the integrity of the blood-brain barrier in vitro. J Neuroimmunol (1996) 2.34
Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man. Pharmacology (1979) 2.31
[Side effects of minocycline in the treatment of acne vulgaris]. Ned Tijdschr Geneeskd (1997) 2.06
Cloxacillin and nafcillin: serum binding and its relationship to antibacterial effect in mice. J Infect Dis (1973) 1.90
Cefazolin and cephradine: relationship between antibacterial activity in vitro and in mice experimentally infected with Escherichia coli. J Infect Dis (1978) 1.79
Pharmacokinetics of brotizolam in healthy subjects following intravenous and oral administration. Br J Clin Pharmacol (1983) 1.78
Pharmacokinetics and metabolism of various benzodiazepines used as hypnotics. Br J Clin Pharmacol (1979) 1.75
The blood-brain barrier in neuroinflammatory diseases. Pharmacol Rev (1997) 1.73
Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure. Br Med J (1967) 1.68
Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice. Antimicrob Agents Chemother (1989) 1.66
Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. Biochem Pharmacol (1984) 1.60
Rectal drug administration: clinical pharmacokinetic considerations. Clin Pharmacokinet (1982) 1.57
Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers. Br J Clin Pharmacol (1979) 1.55
Pharmacokinetics of rectal drug administration, Part I. General considerations and clinical applications of centrally acting drugs. Clin Pharmacokinet (1991) 1.46
Minocycline in the treatment of rheumatoid arthritis: relationship of serum concentrations to efficacy. J Rheumatol (1995) 1.45
Differential effects of enzyme induction on antipyrine metabolite formation. Br J Clin Pharmacol (1982) 1.43
Treatment of suspected sporadic cases of Legionnaires' disease. Lancet (1978) 1.43
Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther (1992) 1.41
Kinetics of antimicrobial action. Rev Infect Dis (1981) 1.41
Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther (1987) 1.41
Automated high-performance liquid chromatographic determination of antipyrine and its main metabolites in plasma, saliva and urine, including 4,4'-dihydroxyantipyrine. J Chromatogr (1983) 1.39
Methodological issues in microdialysis sampling for pharmacokinetic studies. Adv Drug Deliv Rev (2000) 1.37
Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment. Xenobiotica (1979) 1.37
Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. Eur J Clin Pharmacol (1975) 1.35
Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology (2001) 1.32
Clinical pharmacokinetics of hypnotics. Clin Pharmacokinet (1977) 1.32
Interindividual variations in drug disposition. Clinical implications and methods of investigation. Clin Pharmacokinet (1983) 1.32
Nifedipine: kinetics and dynamics in healthy subjects. Clin Pharmacol Ther (1984) 1.32
Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J Clin Invest (2000) 1.32
High prevalence of the neurotrope Exophiala dermatitidis and related oligotrophic black yeasts in sauna facilities. Mycoses (2002) 1.31
Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice. Endocrinology (1998) 1.30
Association of complementation group and mutation type with clinical outcome in fanconi anemia. European Fanconi Anemia Research Group. Blood (2000) 1.29
The relation between plasma and tissue concentrations of antibiotics. Description of a method. J Pharmacokinet Biopharm (1987) 1.27
Patient satisfaction with occupational health physicians, development of a questionnaire. Occup Environ Med (2005) 1.26
Establishment and functional characterization of an in vitro model of the blood-brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes. Eur J Pharm Sci (2001) 1.26
Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection. Antimicrob Agents Chemother (1990) 1.25
The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice. Br J Pharmacol (1999) 1.25
A novel link between Campylobacter jejuni bacteriophage defence, virulence and Guillain-Barré syndrome. Eur J Clin Microbiol Infect Dis (2012) 1.24
Assay of triazolam in plasma by capillary gas chromatography. J Chromatogr (1981) 1.22
Role of granulocytes in experimental Streptococcus sanguis endocarditis. Infect Immun (1982) 1.22
The relative potency of amoxycillin and ampicillin in vitro and in vivo. Scand J Infect Dis (1981) 1.20
Apoptin: therapeutic potential of an early sensor of carcinogenic transformation. Annu Rev Pharmacol Toxicol (2008) 1.20
Cefazolin and cephradine: relationship between serum concentrations and tissue contents in mice. Infection (1978) 1.20
Saturation of the tubular excretion of beta-lactam antibiotics. Br J Clin Pharmacol (1988) 1.20
A quantitative evaluation of pulmonary macrophage kinetics. Cell Tissue Kinet (1983) 1.19
Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther (1991) 1.16
Pharmacokinetic interactions with rifampicin. Clin Pharmacokinet (1977) 1.14
A comparison of the sensitivities of adaptive tracking, eye movement analysis and visual analog lines to the effects of incremental doses of temazepam in healthy volunteers. Clin Pharmacol Ther (1991) 1.14
Effect of amphotericin B, fluconazole and itraconazole on intracellular Candida albicans and germ tube development in macrophages. J Antimicrob Chemother (1990) 1.13
Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier. Brain Res Brain Res Rev (1997) 1.13
Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time. Eur J Clin Pharmacol (1982) 1.13
Comparison of the effect of different chitosan salts and N-trimethyl chitosan chloride on the permeability of intestinal epithelial cells (Caco-2). J Control Release (1998) 1.12
Clinical pharmacokinetics of nitrazepam. Clin Pharmacokinet (1982) 1.11
Lack of bimodality in nifedipine plasma kinetics in a large population of healthy subjects. Biochem Pharmacol (1988) 1.11
Pharmacokinetics of benzodiazepines. Short-acting versus long-acting. Arzneimittelforschung (1980) 1.10
Influence of sex and oral contraceptive steroids on antipyrine metabolite formation. Clin Pharmacol Ther (1982) 1.10
Relationship between permeability status of the blood-brain barrier and in vitro permeability coefficient of a drug. Eur J Pharm Sci (2000) 1.10
Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. Br J Clin Pharmacol (2000) 1.09
Modulation of the intestinal flora of mice by parenteral treatment with broad-spectrum cephalosporins. Antimicrob Agents Chemother (1991) 1.09
Uptake of azithromycin by human monocytes and enhanced intracellular antibacterial activity against Staphylococcus aureus. Antimicrob Agents Chemother (1993) 1.08
Liquid chromatographic determination of nifedipine in plasma and of its main metabolite in urine. J Chromatogr (1984) 1.07
Influence of rifampicin on drug metabolism: differences between hexobarbital and antipyrine. Clin Pharmacol Ther (1977) 1.06
Pharmacokinetics of temazepam compared with other benzodiazepine hypnotics--some clinical consequences. Acta Psychiatr Scand Suppl (1986) 1.06
Comparative study of the effects of four cephalosporins against Escherichia coli in vitro and in vivo. Antimicrob Agents Chemother (1990) 1.06
The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation. J Psychopharmacol (1999) 1.05
Pharmacokinetics of methohexitone following intravenous infusion in humans. Br J Anaesth (1976) 1.05
Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approach. Br J Clin Pharmacol (1988) 1.04
Pharmacokinetic-pharmacodynamic relationship of the cardiovascular effects of adenosine A1 receptor agonist N6-cyclopentyladenosine in the rat. J Pharmacol Exp Ther (1994) 1.04
Quantitative effect of granulocytes on antibiotic treatment of experimental staphylococcal infection. Antimicrob Agents Chemother (1987) 1.03
Effect of endotoxin on permeability of bovine cerebral endothelial cell layers in vitro. J Pharmacol Exp Ther (1996) 1.03
Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design. J Pharmacol Exp Ther (1989) 1.03
Blood levels of rifampicin, desacetylrifampicin and isoniazid during combined therapy. J Antimicrob Chemother (1979) 1.03
Pharmacokinetic-pharmacodynamic modeling of CNS drug effects: an overview. Pharmacol Ther (1988) 1.02
Eicosanoid production by rat cerebral endothelial cells: stimulation by lipopolysaccharide, interleukin-1 and interleukin-6. J Neuroimmunol (1995) 1.01
Antibiotic-induced lipopolysaccharide (LPS) release from Salmonella typhi: delay between killing by ceftazidime and imipenem and release of LPS. Antimicrob Agents Chemother (1998) 1.01
Comparative pharmacokinetics of brotizolam and triazolam in healthy subjects. Br J Clin Pharmacol (1983) 1.01
In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin. Eur J Pharm Sci (2000) 1.01
Pharmacokinetics of cloxacillin in patients on chronic intermittent haemodialysis and in healthy subjects. Chemotherapy (1973) 1.00
Astrocytes increase the functional expression of P-glycoprotein in an in vitro model of the blood-brain barrier. Pharm Res (2000) 1.00
Pharmacokinetics of flucloxacillin and cloxacillin in healthy subjects and patients on chronic intermittent haemodialysis. Br J Clin Pharmacol (1975) 1.00
Role of granulocytes in the prevention and therapy of experimental Streptococcus sanguis endocarditis in rabbits. Antimicrob Agents Chemother (1984) 0.99
Effect of degree of quaternization of N-trimethyl chitosan chloride for enhanced transport of hydrophilic compounds across intestinal caco-2 cell monolayers. J Control Release (2000) 0.99
Quantitative determination of the effect of granulocytes on the course of experimental infections during antibiotic treatment. Infection (1984) 0.99
Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship. Clin Pharmacol Ther (1985) 0.99
A fallacy of the multiplicative QALY model for low-quality weights in students and patients judging hypothetical health states. Int J Technol Assess Health Care (2001) 0.98
Effect of age and liver cirrhosis on the pharmacokinetics of nitrazepam. Br J Clin Pharmacol (1983) 0.98